Lessons learned from research on choroideremia.

Area of Science:

• Ophthalmology
• Genetics
• Clinical Research Ethics

Background:

• Choroideremia (CHM) is a rare X-linked genetic disorder causing progressive vision loss.
• Decades of research have explored therapeutic interventions for CHM.
• Investigator-initiated clinical trials present unique ethical and logistical considerations.

Purpose of the Study:

• To reflect on lessons learned from a Phase IB clinical trial of ocular gene therapy for choroideremia.
• To emphasize the importance of addressing psychological harm in clinical research participants.
• To evaluate the potential of gene replacement and antisense oligonucleotide therapies for CHM.

Main Methods:

• Retrospective analysis of experiences from an investigator-sponsored Phase IB ocular gene therapy trial for CHM.
• Consideration of ethical implications, including investigator bias and patient well-being.
• Review of preliminary data and potential alternative therapeutic strategies.

Main Results:

• Clinical research requires careful attention to potential unintended psychological harm to participants.
• Preliminary data may not fully predict patient risks in early-phase trials.
• Separation of the principal investigator and treating physician roles is crucial in investigator-sponsored trials.
• Gene replacement using AAV vectors and antisense oligonucleotide therapy are potential genetic treatments for CHM.

Conclusions:

• Ethical oversight and participant support are paramount in gene therapy trials for rare diseases like choroideremia.
• Investigator bias must be mitigated through clear role separation.
• Multiple genetic therapeutic avenues, including gene replacement and oligonucleotide-based approaches, warrant further investigation for choroideremia.